The immune tolerance induction (ITI) dose debate: Does the International ITI Study provide a clearer picture?

Haemophilia

Volumn 19, Issue SUPPL. 1, 2013, Pages 12-17

  Ettingshausen, C Escuriola ^a   Kreuz, W ^a  

^a HZRM Haemophilia Centre Rhein Main Frankfurt   (Germany)

Author keywords

Factor VIII; Haemophilia A; Immune tolerance induction; Inhibitors

Indexed keywords

PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 8;

CLINICAL PROTOCOL; HUMAN; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

COAGULANTS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; PROGNOSIS;

EID: 84871667083     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12051     Document Type: Review

References (15)

1. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, Van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
2. Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia 2010; 16: 71-9.
3. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
4. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77(Suppl. 1): 33-7.
5. Hay CR, DiMichele DM, on behalf of the International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
6. Brackmann HH, Schwaab R, Effenberger W, Hess L, Hanfland P, Oldenburg J. Antibodies to factor VIII in hemophilia A patients. Vox Sang 2000; 78(Suppl. 2): 187-90.
7. Unuvar A, Kavakli K, Baytan B et al. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors. Haemophilia 2008; 14: 315-22.
8. Kurth M, Puetz J, Kouides P et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost 2011; 9: 2229-34.
9. ®) in 14 patients with severe haemophilia A. Haemophilia 2011; 17: e837-40.
10. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008; 14: 295-302.
11. Kurth MA, Dimichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-5.
12. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
13. Gringeri A, Musso R, Mazzucconi MG et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
14. Kreuz W, Escuriola-Ettingshausen C, Auerswald G et al. Immune tolerance induction (ITI) in haemophilia A with inhibitors: the choice of concentrate affecting success. Haematologica 2001; 86(Suppl. 4): 16-20.
15. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.